XBiotech Inc. (XBIT) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. XBiotech Inc. is a pre-market biopharmaceutical company focused on developing True Human™ monoclonal antibodies. The company operates as a single segment with headquarters in Austin, Texas. As of the filing date, the company had 87 employees and 30,487,731 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5.5) million | $(10.9) million |
| Net Loss Per Share | $(0.18) | $(0.36) |
| Operating Expenses | $6.3 million | $13.6 million |
| Cash and Cash Equivalents | $115.5 million | $155.9 million |
| Net Cash Used in Operating Activities | $(9.0) million | $(6.7) million |
| Total Assets | $139.8 million | $150.1 million (Dec 31, 2025) |
| Total Liabilities | $4.8 million | $9.7 million (Dec 31, 2025) |
Material Changes vs. Prior Period
- Significant Expense Reduction: Total operating expenses decreased by approximately 54% year-over-year, driven primarily by a one-time $4.0 million bonus and $3.0 million in stock-based compensation awarded to the former CEO in Q1 2025, which were not repeated in Q1 2026.
- Research & Development (R&D): R&D expenses dropped from $11.6 million to $5.2 million. This 55% decrease is largely attributable to the absence of the former CEO's bonus and stock compensation allocated to R&D in the prior year.
- Foreign Exchange Impact: The company recorded a foreign exchange loss of $1.1 million in Q1 2026, compared to a gain of $0.3 million in Q1 2025, due to fluctuations between the U.S. and Canadian dollars.
- Liquidity: Cash balances decreased by $10.1 million during the quarter, primarily due to operating losses and the payment of the former CEO's 2025 annual bonus in January 2026.
Outlook, Risks, and Management Commentary
- Revenue Outlook: Management does not expect to generate any revenue in 2026. The company anticipates incurring significant and increasing operating losses as it advances drug candidates through clinical trials.
- Liquidity Position: With $115.5 million in cash, management believes the company has sufficient liquidity to fund operations for at least the next 12 months and achieve major inflection points in clinical studies.
- Pipeline Status: The company has completed a Phase II clinical study in oncology and is engaging with the FDA to define the regulatory path forward. It is also advancing an anti-IL-1a antibody into a Phase I study in neurology.
- Risk Factors: Key risks include the uncertainty of clinical trial success, the ability to obtain regulatory approval, dependence on financing to fund operations, and potential infringement of intellectual property rights. The company notes that it may never achieve profitability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $115.5 million cash balance against projected burn rates for upcoming clinical trials.
- One-Time Expenses: Confirm that the Q1 2025 expenses related to the former CEO's departure are non-recurring and do not distort the baseline operating cost structure.
- Regulatory Path: Monitor the outcome of the company's engagement with the FDA regarding the Phase II oncology study results.
- Foreign Exchange Exposure: Assess the impact of continued USD/CAD fluctuations on future financial statements given the company's Canadian incorporation and banking.
- Debt Status: Confirm that the related-party convertible loan mentioned in prior periods has been fully repaid and no new debt obligations exist (filing indicates no outstanding debt).